Vancomycin HCI vials

Vancomycin HCI vials
Product Description

Vancomycin hydrochloride (HCI) is a glycopeptide antibiotic active against a wide variety of aerobic Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroids, enterococci, (e.g. Enterococcus faecalis), Streptococcus bovis and viridans group streptococci.

Indication: Used in the treatment of patients with severe and/or methicillin-resistant staphylococcal infections (endocarditis, bone infections, lower respiratory tract infections, septicemia and skin structure infections) and treatment of preoperative prophylaxis of streptococcal or diphteroid endocarditis where other antibiotics cannot be used due to intolerance or drug resistance. It may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis.

Application: Administered as intravenous infusions for systemic therapy. May be administered orally for treatment of antibiotic-associated pseudomembranous colitis.

Shelf-life: 24 months

Storage conditions: Between 15-25°C (59-77°F) depending on territory

For further information contact us at [email protected] 

or access our product sheet online https://xellia.com/products/Vancomycin%20HCI%20vials/

Read more Show less

Xellia Pharmaceuticals ApS

  • DK
  • 2015
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Finished Formulation products Distributor/Buyer
View company profile
Categories
more categories Show less

Xellia Pharmaceuticals ApS

  • DK
  • 2015
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Finished Formulation products Distributor/Buyer
View company profile

More Products from Xellia Pharmaceuticals ApS (21)

  • Bacitracin vials

    Product Bacitracin vials

    Bacitracin is comprised of a polypeptide complex and bacitracin A is the major component in this complex active against a variety of Gram-positive bacteria and a few Gram-negative bacteria, however only staphylococcal infections qualify for the systemic therapy.

    Indi...
  • Colistimethate sodium lyophilized vials

    Product Colistimethate sodium lyophilized vials

    Colistimethate sodium is a prodrug of colistin, which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and especially Pseudomonas aeruginosa.

    Indication:&nbs...
  • Daptomycin RT

    Product Daptomycin RT

    Daptomycin is a lipopeptide antibacterial agent active against gram-positive bacteria.
    Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of gram-positive bacteria such as Staphylococcus aureus&nbs...
  • Daptomycin vials

    Product Daptomycin vials

    Daptomycin is a lipopeptide antibacterial agent active against Gram-positive bacteria.

    Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of Gram-positive bacteria such as Staphylococcus au...
  • Micafungin vials

    Product Micafungin vials

    Micafungin is a semisynthetic lipopeptide from the echinocandin class of antifungal agents. Micafungin is active against most isolates of the following Candida species such as Candida albicans, Candida glabrata, Candida guiliermondii, Candida krusei, Candida parapsilosis and Candida tropicalis.
    ...
  • Polymyxin B vials

    Product Polymyxin B vials

    Polymyxin B is a mixture of the sulfates of polypeptide antibiotics active against Gram-negative bacteria.

    Indication: Used in the treatment of patients with acute urinary, meningeal or blood-stream infections due to susceptible strains such as Pseudomonas aerugino...
  • Voriconazole vials

    Product Voriconazole vials

    Voriconazole is a broad spectrum triazole antifungal agent.

    Indication: Used in the treatment of patients with progressive, possibly life-threatening fungal infections such as candidaemia in non-neutropenic patients, invasive candidiasis in skin, abdomen, kidney, bladd...
  • Colistimethate sodium dry-filled vials

    Product Colistimethate sodium dry-filled vials

    Colistimethate sodium is a prodrug of colistin which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.
    Indication: Used in the treatment of patients with serious infectio...
  • Vancomycin Injection, Ready to Use

    Product Vancomycin Injection, Ready to Use

    Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, such as Staphylococcus aureus and Staphylococcus epidermidis (including susceptible methicillin-resistant strains), but also active against corynebacterium, ent...
  • Amphotericin B

    Product Amphotericin B

    Amphotericin B is a mixture of polyenes active against a wide variety of fungi e.g. Aspergillus, Candida and Cryptococcus species.

    Indication: Used in the treatment of severe, invasive, potentially life-threatening fungal infections (mycosis) typically in immunocompromised patients. q...
  • Bacitracin

    Product Bacitracin

    Bacitracin is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci.

    Indication: Used locally for the treatment of infections of the skin, ear and eye or for intramuscular use in infants for the...
  • Bacitracin zinc

    Product Bacitracin zinc

    Bacitracin zinc is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci. The zinc complex adds stability to the component, making bacitracin zinc more stable compared to bacitracin.

    Indication: Used in the treatm...
show all 21 other products

Xellia Pharmaceuticals ApS resources (2)

  • Xellia Pharmaceuticals welcomes Michael Kocher as its new Chief Executive Officer

    News Xellia Pharmaceuticals welcomes Michael Kocher as its new Chief Executive Officer

    Copenhagen, Denmark, 2 October 2023 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies, today welcomes Michael Kocher as its new Chief Executive Officer. With more than a decade of experience in commercial leadership roles at Novartis and Sandoz, Michael Kocher has significant expertise in the complexities of the global pharmaceutical landscape. His tenure at Sandoz, where he served as Global Head of Commercial Operations and subsequently as Global Head of B2B, underscored his pivotal role in transforming the company into a leading global partner within the industry. A native of Germany and a trained chemist, Michael Kocher's expertise and vision align with Xellia Pharmaceuticals' commitment to delivering anti-infective treatments and critical care therapies.
    3 Oct 2023
  • Xellia Corporate Introduction

    Technical Data Xellia Corporate Introduction

    Xellia Pharmaceuticals is a specialty pharmaceutical company developing,manufacturing and commercializing anti-infective treatments againstserious and often life-threatening bacterial and fungal infections. Xellia isa world-leading trusted supplier of several important established antiinfectivedrugs, comprising active pharmaceutical ingredients as well asfinished dosage forms, where the majority are injectable drug products.Headquartered in Copenhagen, Denmark and owned by Novo HoldingsA/S, Xellia Pharmaceuticals has more than 1800 employees globally.From state-of-the-art manufacturing sites in the U.S., China, Denmarkand Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticalsexcels within innovative product development to deliver high qualityproducts to its customers.